ClariTrial | Search Clinical Trials

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

35 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants139 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

1–15 of 35

Explore/autoimmune immunology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

35 results for “autoimmune immunology” · Recruiting · Phase 3 · Phase 2

Page 1 of 3

Recruiting

Immunosuppression and COVID-19 Boosters

Phase 3COVID-19

diphtheria and tetanus toxoids (adsorbed) vaccineCOVID-19 vaccine

Kirby Institute320 participants5 sites · AustraliaCompletes Dec 2026

Compare CT.gov Full analysis →

Recruiting

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

Phase 2Systemic Lupus Erythematosus

BI 3000202Placebo

Boehringer Ingelheim405 participants139 sites · United States, Argentina, AustraliaCompletes Feb 2029

Compare CT.gov Full analysis →

Recruiting

A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus

Phase 1Phase 2Systemic Lupus Erythematosus

CD19 Universal CAR-γδ T Cells

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology15 participants1 site · ChinaCompletes Dec 2025

Compare CT.gov Full analysis →

Recruiting

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Phase 2IgG4 Related DiseaseB-cell Mediated Autoimmune Disorders

Anti-BCMA-CD19 CAR-T cells

Chinese PLA General Hospital9 participants1 site · ChinaCompletes Sep 2027

Compare CT.gov Full analysis →

Recruiting

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Phase 2Multiple SclerosisClinically Isolated Syndrome of Demyelination

Tyruko Injectable ProductPlacebo

Queen Mary University of London40 participants2 sites · United KingdomCompletes Oct 2027

Compare CT.gov Full analysis →

Recruiting

An Artificial Intelligence-powered Approach to Precision Immunotherapy of Human Arthritis

Phase 2Rheumatoid Arthritis (RA)Rheumatology

dnaJP1Placebo

Prof Salvatore Albani124 participants1 site · SingaporeCompletes Nov 2028

Compare CT.gov Full analysis →

Recruiting

Rescue of Nephrons With ALE.F02 (RENAL-F02)

Phase 2Glomerulonephritis Rapidly Progressive

ALE.F02RituximabGlucoCorticoid+3 more

Alentis Therapeutics AG80 participants49 sites · Czechia, Denmark, FranceCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS

Phase 3Oligoarthritis, JuvenilePolyarthritis, Juvenile, Rheumatoid Factor Negative

EtanerceptMethotrexateIntra-articular corticosteroid injections

Istituto Giannina Gaslini260 participants1 site · ItalyCompletes Feb 2025

Compare CT.gov Full analysis →

Recruiting

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Phase 2Phase 3Type 1 Diabetes Mellitus

Dimethyl Fumarate Enteric-coated CapsulesInsulin

Nanjing Medical University96 participants1 site · ChinaCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

VIBRANT: VIB4920 for Active Lupus Nephritis

Phase 2Lupus Nephritis

VIB4920Placebo for VIB4920

National Institute of Allergy and Infectious Diseases (NIAID)74 participants17 sites · United StatesCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

Phase 2Lymphoproliferative DisordersAutoimmune LymphoproliferativeImmune System Diseases

Busulfan test doseFludarabineBusulfan+6 more

National Cancer Institute (NCI)66 participants1 site · United StatesCompletes Oct 2026

Compare CT.gov Full analysis →

Recruiting

Efficacy, Safety and Immunological Evaluation of Upadacitinib for Relapsing Polychondritis

Phase 1Phase 2Relapsing Polychondritis

Upadacitinibcorticosteroids and immunosuppressants

Peking University People's Hospital30 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis

Phase 2Giant Cell Arteritis (GCA)

TocilizumabDiscontinue Tocilizumab

National Institute of Allergy and Infectious Diseases (NIAID)78 participants7 sites · United StatesCompletes Jun 2027

Compare CT.gov Full analysis →

Recruiting

Abatacept for the Treatment of Common Variable Immunodeficiency With Interstitial Lung Disease

Phase 2Interstitial Lung DiseaseCommon Variable Immunodeficiency

AbataceptPlacebo

Children's Hospital Medical Center, Cincinnati38 participants6 sites · United StatesCompletes Jul 2026

Compare CT.gov Full analysis →

Recruiting

A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis

Phase 2Giant Cell Arteritis

AzaFolFDG

Insel Gruppe AG, University Hospital Bern70 participants1 site · SwitzerlandCompletes May 2029

Compare CT.gov Full analysis →

1–15 of 35